Angiozyme: A novel angiogenesis inhibitor

Current oncology reports

Volumn 3, Issue 2, 2001, Pages 141-146

  Weng, David E ^a   Usman, Nassim ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Sirna Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOZYME; GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; RIBOZYME; VASCULOTROPIN RECEPTOR;

ANIMAL; CLINICAL TRIAL; DISEASE COURSE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; HUMAN; MOUSE; NEOPLASM; PHYSIOLOGY; RAT; REVIEW; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICE; NEOPLASMS; RATS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RNA, CATALYTIC;

EID: 0035290919     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-001-0014-7     Document Type: Review

References (33)

1. 1. J Folkman 1971 Tumor angiogenesis: therapeutic implications N Engl J Med 285 1182 1186 4938153 1:STN:280:DyaE38%2FgvVCqsQ%3D%3D 10.1056/NEJM197108122850711 Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182–1186.
2. 2. Y Ohta Y Tomita M Oda 1999 Tumor angiogenesis and recurrence in stage I non-small cell lung cancer Ann Thorac Surg 68 1034 1038 10510003 10.1016/S0003-4975(99)00611-6 1:STN:280:DyaK1MvjslOjsA%3D%3D Ohta Y, Tomita Y, Oda M, et al.: Tumor angiogenesis and recurrence in stage I non-small cell lung cancer. Ann Thorac Surg 1999, 68:1034–1038.
3. 3. B Linderholm K Grankvist N Wilking 2000 Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment J Clin Oncol 18 1423 1431 10735889 1:CAS:528:DC%2BD3cXivVeisro%3D This clinical study demonstrates the importance of VEGF as an independent prognostic marker for node-positive breast cancer Linderholm B, Grankvist K, Wilking N, et al.: Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 2000, 18:1423–1431. This clinical study demonstrates the importance of VEGF as an independent prognostic marker for node-positive breast cancer.
4. 4. H Imoto T Osaki S Taga 1998 Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma J Thorac Cardiovasc Surg 115 1007 10014 9605068 10.1016/S0022-5223(98)70398-8 1:STN:280:DyaK1c3ms1Wjtg%3D%3D Imoto H, Osaki T, Taga S, et al.: Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 1998, 115:1007–10014.
5. 5. J Jacobsen T Rasmuson K Grankvist 2000 Vascular endothelial growth factor as prognostic factor in renal cell carcinoma J Urol 163 343 347 10604387 10.1016/S0022-5347(05)68049-4 1:STN:280:DC%2BD3c%2FmslyktA%3D%3D Jacobsen J, Rasmuson T, Grankvist K, et al.: Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000, 163:343–347.
6. 6. N Ferrara K Alitalo 1999 Clinical applications of angiogenic growth factors and their inhibitors Nat Med 5 1359 1364 10581076 10.1038/70928 1:CAS:528:DyaK1MXnvFCqtrw%3D Concise review of the multiple roles for manipulation of the VEGF pathway in experimental therapeutics for many human diseases Ferrara N, Alitalo K: Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999, 5:1359–1364. Concise review of the multiple roles for manipulation of the VEGF pathway in experimental therapeutics for many human diseases.
7. 7. Antiangiogenesis Information [database online]. Bethesda, MD: National Cancer Institute; 2000. Available at http:// cancertrials.nci.nih.gov/news/angio/index.htm Updated summary of the ongoing clinical trials for angiogenesis inhibitors for cancer therapy, accessible via the Internet.
8. 8. ME Beckner 1999 Factors promoting tumor angiogenesis Cancer Invest 17 594 623 10592767 1:CAS:528:DC%2BD3cXhsVyqtg%3D%3D 10.3109/07357909909032845 Excellent summary of the multiple factors interacting to influence the process of angiogenesis Beckner ME: Factors promoting tumor angiogenesis. Cancer Invest 1999, 17:594–623. Excellent summary of the multiple factors interacting to influence the process of angiogenesis.
9. 9. PA Pavco KS Bouhana AM Gallegos 2000 Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors Clin Cancer Res 6 2094 2103 10815937 1:CAS:528:DC%2BD3cXktVWit74%3D Pavco PA, Bouhana KS, Gallegos AM, et al.: Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin Cancer Res 2000, 6:2094–2103.
10. 10. DR Senger SJ Galli AM Dvorak 1983 Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid Science 219 983 985 6823562 10.1126/science.6823562 1:STN:280:DyaL3s7hvF2mtw%3D%3D Senger DR, Galli SJ, Dvorak AM, et al.: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983–985.
11. 11. DW Leung G Cachianes WJ Kuang 1989 Vascular endothelial growth factor is a secreted angiogenic mitogen Science 246 1306 1309 2479986 10.1126/science.2479986 1:CAS:528:DyaK3cXls1GltLo%3D Leung DW, Cachianes G, Kuang WJ, et al.: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306–1309.
12. 12. M Shibuya 1995 Role of VEGF-flt receptor system in normal and tumor angiogenesis Adv Cancer Res 67 281 316 8571818 1:CAS:528:DyaK28XktlejsQ%3D%3D 10.1016/S0065-230X(08)60716-2 Shibuya M: Role of VEGF-flt receptor system in normal and tumor angiogenesis. Adv Cancer Res 1995, 67:281–316.
13. 13. LM Ellis Y Takahashi W Liu RM Shaeen 2000 Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications Oncologist 5 suppl 1 11 15 10804085 10.1634/theoncologist.5-suppl_1-11 1:CAS:528:DC%2BD3cXjsFartr0%3D Ellis LM, Takahashi Y, Liu W, Shaeen RM: Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist 2000, 5 (suppl 1):11–15.
14. 14. LE Benjamin D Golijanin A Itin 1999 Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal J Clin Invest 103 159 165 9916127 1:CAS:528:DyaK1MXltFeruw%3D%3D Benjamin LE, Golijanin D, Itin A, et al.: Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999, 103:159–165.
15. 15. LB Jakeman J Winer GL Bennett 1992 Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues J Clin Invest 89 244 253 1729274 1:CAS:528:DyaK38XnslWlsg%3D%3D Jakeman LB, Winer J, Bennett GL, et al.: Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest 1992, 89:244–253.
16. 16. G Neufeld T Cohen S Gebrinovtch Z Poltorak 1999 Vascular endothelial growth factor (VEGF) and its receptors Faseb J 13 9 22 9872925 1:CAS:528:DyaK1MXlt1ygsQ%3D%3D Neufeld G, Cohen T, Gebrinovtch S, Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. Faseb J 1999, 13:9–22.
17. 17. D Gabrilovich T Ishida T Oyama 1998 Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo Blood 92 4150 4166 9834220 1:CAS:528:DyaK1cXnslylsLw%3D This article highlights the potential importance of VEGF as an immunosuppressive agent in cancer biology Gabrilovich D, Ishida T, Oyama T, et al.: Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998, 92:4150–4166. This article highlights the potential importance of VEGF as an immunosuppressive agent in cancer biology.
18. 18. V Speirs SL Atkin 1999 Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours Br J Cancer 80 898 903 10360672 10.1038/sj.bjc.6690438 1:CAS:528:DyaK1MXjsV2ru7Y%3D Speirs V, Atkin SL: Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours. Br J Cancer 1999, 80:898–903.
19. 19. M Decaussin H Sartelet C Robert 1999 Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival J Pathol 188 369 377 10440746 10.1002/(SICI)1096-9896(199908)188:4<369::AID-PATH381>3.0.CO;2-X 1:CAS:528:DyaK1MXlt1ajurY%3D Decaussin M, Sartelet H, Robert C, et al.: Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J Pathol 1999, 188:369–377.
20. 20. B Liu HM Earl D Baban 1995 Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF Biochem Biophys Res Commun 217 721 727 8554590 10.1006/bbrc.1995.2832 1:CAS:528:DyaK28XhsVSlsw%3D%3D Liu B, Earl HM, Baban D, et al.: Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. Biochem Biophys Res Commun 1995, 217:721–727.
21. 21. F Shalaby J Ho WL Standford 1997 A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis Cell 89 981 990 9200616 10.1016/S0092-8674(00)80283-4 1:CAS:528:DyaK2sXktFakt70%3D Shalaby F, Ho J, Standford WL, et al.: A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis. Cell 1997, 89:981–990.
22. 22. GH Fong J Rossant M Gertsenstein ML Breitman 1995 Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium Nature 376 66 70 7596436 10.1038/376066a0 1:CAS:528:DyaK2MXmvVKjsrs%3D Fong GH, Rossant J, Gertsenstein M, Breitman ML: Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995, 376:66–70.
23. 23. B Barleon G Siemeister G Martiny-Baron 1997 Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells Cancer Res 57 5421 5425 9393770 1:CAS:528:DyaK2sXnslGqs7o%3D Barleon B, Siemeister G, Martiny-Baron G, et al.: Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells. Cancer Res 1997, 57:5421–5425.
24. 24. KJ Kim J Winer M Armanini 1993 Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature 362 841 844 7683111 10.1038/362841a0 1:CAS:528:DyaK3sXktVKju7s%3D Kim KJ, Winer J, Armanini M, et al.: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841–844.
25. 25. HT Zhang P Craft PA Scott 1995 Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells J Natl Cancer Inst 87 213 219 7535859 10.1093/jnci/87.3.213 1:CAS:528:DyaK2MXkt1ertrg%3D Zhang HT, Craft P, Scott PA, et al.: Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst 1995, 87:213–219.
26. 26. AJ Zaug MD Been TR Cech 1986 The Tetrahymena ribzyme acts like an RNA restriction endonuclease Nature 324 429 433 3537808 10.1038/324429a0 1:CAS:528:DyaL2sXmtlGhug%3D%3D Zaug AJ, Been MD, Cech TR: The Tetrahymena ribzyme acts like an RNA restriction endonuclease. Nature 1986, 324:429–433.
27. 27. M Baer S Altman 1985 A catalytic RNA and its gene from Salmonella typhimurium Science 228 998 1002 10.1126/science.2408335 Baer M, Altman S: A catalytic RNA and its gene from Salmonella typhimurium. Science 1985, 228:998–1002.
28. 28. U Usman D Stinchcomb 1996 Design, synthesis and function of therapeutic hammerhead ribozymes R Eckstein D Lilley Nucleic Acids and Molecular Biology Springer-Verlag Berlin 243 264 Usman U, Stinchcomb D: Design, synthesis and function of therapeutic hammerhead ribozymes. In Nucleic Acids and Molecular Biology. Edited by Eckstein R, Lilley D. Berlin: Springer-Verlag; 1996:243–264.
29. 29. N Usman L Beigelman JA McSwiggen 1996 Hammerhead ribozyme engineering Curr Opin Struct Biol 6 527 533 8794164 10.1016/S0959-440X(96)80119-9 1:CAS:528:DyaK28Xlsleit7s%3D Usman N, Beigelman L, McSwiggen JA: Hammerhead ribozyme engineering. Curr Opin Struct Biol 1996, 6:527–533.
30. 30. PL Fell A Hudson MA Reynolds 1997 Cellular uptake properties of a 2′-amino/2′-O-methyl-modified chimeric hammerhead ribozyme targeted to the epidermal growth factor receptor mRNA Antisense Nucleic Acid Drug Dev 7 319 326 9303183 1:CAS:528:DyaK2sXmtFahur8%3D Fell PL, Hudson A, Reynolds MA, et al.: Cellular uptake properties of a 2′-amino/2′-O-methyl-modified chimeric hammerhead ribozyme targeted to the epidermal growth factor receptor mRNA. Antisense Nucleic Acid Drug Dev 1997, 7:319–326.
31. 31. TJ Parry C Cushman AM Gallegos 1999 Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA Nucleic Acids Res 27 2569 2577 10373571 10.1093/nar/27.13.2569 1:CAS:528:DyaK1MXksVKqsbo%3D Parry TJ, Cushman C, Gallegos AM, et al.: Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA. Nucleic Acids Res 1999, 27:2569–2577.
32. 32. JA Sandberg KS Bouhana AM Gallegos 1999 Pharmacokinetics of an antiangiogenic ribozyme (ANGIOZYME) in the mouse Antisense Nucleic Acid Drug Dev 9 271 277 10435752 1:CAS:528:DyaK1MXksFCjsbg%3D Sandberg JA, Bouhana KS, Gallegos AM, et al.: Pharmacokinetics of an antiangiogenic ribozyme (ANGIOZYME) in the mouse. Antisense Nucleic Acid Drug Dev 1999, 9:271–277.
33. 33. VP Parker JA Sandberg J Smith 2000 Phase I and pharmacokinetic studies of Angiozyme, a synthetic ribozyme targeting the VEGF receptor Flt-1 [abstract] Proc ASCO 19 703a 703a Parker VP, Sandberg JA, Smith J, et al.: Phase I and pharmacokinetic studies of Angiozyme, a synthetic ribozyme targeting the VEGF receptor Flt-1 [abstract]. Proc ASCO 2000, 19:703a.